Empower Clinics Inc. (CSE:CBDT, OTCQB:EPWCF) has announced the appointment of Dr Tyler Coupal as the company’s first British Columbia Medical Director, effective February 1, 2022.
Empower said its intention is for Coupal to lead the launch of coronavirus (COVID-19) testing services within the province, as The College of Physicians and Surgeons of British Columbia requires all facilities to be recognized under its Diagnostic Accreditation Program (DAP).
“Our team's goal is to help reopen local economies, especially hard-hit industries in tourism and hospitality,” Empower Clinics CEO Steven McAuley said in a statement.
READ: Empower Clinics says MediSure Canada receives Health Canada licences for two new best-in-class products
“DAP certification will allow us to capitalize on the pressing demand for more COVID-19 testing within Empower's home province,” McAuley added.
The company noted that a medical director, who is a registered physician, is required to oversee all specimen collection procedures, transportation, and laboratory processing as part of the DAP, and upon recognition of DAP accreditation, Empower Clinics will be in the position to offer COVID-19 testing in British Columbia.
It added that it hopes to expand the supply of available COVID-19 testing, both polymerase chain reaction (PCR) and Rapid Antigen, within the province through approved sites.
As well, Empower Clinics reported that it has granted, effective January 20, 2022, a total of 200,000 stock options to certain company contractors.
Each option is exercisable into one Empower Clinics common share at a price of $0.295 per share, being the closing price of the shares on the Canadian Securities Exchange on the date of grant and the trading date before the date of grant for a period of five years from the date of grant. Shares will be subject to a hold period of four months beginning on the date of grant of the options.
Empower Clinics is an integrated healthcare company that is aggressively growing its clinical and digital presence across North America. The company's Health & Wellness and Diagnostics & Technology business units are positioned to positively impact the integrated health of its patients, while simultaneously providing long-term value for its shareholders.
Contact Sean at sean@proactiveinvestors.com